Dugi K A, Vaisman B L, Sakai N, Knapper C L, Meyn S M, Brewer H B, Santamarina-Fojo S
Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
J Lipid Res. 1997 Sep;38(9):1822-32.
In order to evaluate the coordinate role that hepatic lipase (HL) and lecithin:cholesterol acyltransferase (LCAT) play in modulating HDL particle heterogeneity and function in vivo we utilized recombinant adenovirus to express HL in control and LCAT transgenic mice. Adenovirus-mediated expression of human HL in control (n = 4, LCAT activity = 42 +/- 1 nmol/ml per h) and LCAT-tg mice (n = 4, LCAT activity = 3566 +/- 93 nmol/ml per h) resulted in post heparin HL activities of 24,358 +/- 6080 and 27,266 +/- 7985 nmol/ml per min, respectively. Overexpression of HL led to significant reductions in total cholesterol, phospholipids, and HDL cholesterol in both LCAT-tg (62, 62, and 63%, P < 0.05) and control mice (68, 63, and 78%, P < 0.01) as well as to the formation of more homogenous HDL. However, compared to control animals, the reductions in the plasma concentrations of HDL-cholesterol and apoA-I were less in LCAT-tg mice (HDL-cholesterol: -62 +/- 15% vs. -78 +/- 15%, P = 0.18; apoA-I: -36 +/- 7% vs. -76 +/- 8%, P < 0.0005). Gel filtration analysis revealed that in LCAT-tg mice the apoE-rich HDL1 was preferentially reduced by expression of HL in vivo. Compared to control mice the reduction in the apoA-I/A-II HDL in transgenic mice was significantly less indicating that a subset of HDL in LCAT transgenic mice are resistant to the action of HL. These combined data support a role for both HL and LCAT in modulating HDL heterogeneity and function, properties which may ultimately affect the ability of LCAT transgenic mouse HDL to function in the process of reverse cholesterol transport.
为了评估肝脂酶(HL)和卵磷脂胆固醇酰基转移酶(LCAT)在体内调节高密度脂蛋白(HDL)颗粒异质性和功能中所起的协同作用,我们利用重组腺病毒在对照小鼠和LCAT转基因小鼠中表达HL。腺病毒介导的人HL在对照小鼠(n = 4,LCAT活性 = 42 ± 1 nmol/ml每小时)和LCAT转基因小鼠(n = 4,LCAT活性 = 3566 ± 93 nmol/ml每小时)中的表达,导致肝素后HL活性分别为24,358 ± 6080和27,266 ± 7985 nmol/ml每分钟。HL的过表达导致LCAT转基因小鼠(分别降低62%、62%和63%,P < 0.05)和对照小鼠(分别降低68%、63%和78%,P < 0.01)的总胆固醇、磷脂和HDL胆固醇显著降低,同时导致形成更均一的HDL。然而,与对照动物相比,LCAT转基因小鼠中HDL胆固醇和载脂蛋白A-I的血浆浓度降低幅度较小(HDL胆固醇:-62 ± 15%对-78 ± 15%,P = 0.18;载脂蛋白A-I:-36 ± 7%对-76 ± 8%,P < 0.0005)。凝胶过滤分析显示,在LCAT转基因小鼠中,富含载脂蛋白E的HDL1在体内因HL的表达而优先减少。与对照小鼠相比,转基因小鼠中载脂蛋白A-I/载脂蛋白A-II HDL的减少显著较少,表明LCAT转基因小鼠中的一部分HDL对HL的作用具有抗性。这些综合数据支持HL和LCAT在调节HDL异质性和功能中均发挥作用,这些特性最终可能影响LCAT转基因小鼠HDL在逆向胆固醇转运过程中的功能能力。